Corcept Therapeutics Inc. (CORT)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Corcept Therapeutics Inc. (CORT)
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Key Insights
Critical company metrics and information
Share Price
$60.78Market Cap
$6.37 BillionTotal Outstanding Shares
104.78 Million SharesTotal Employees
352Dividend
No dividendIPO Date
April 14, 2004SIC Description
Pharmaceutical PreparationsHomepage
https://www.corcept.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities, Continuing | $144.65 Million |
Net Cash Flow From Investing Activities, Continuing | $-96.15 Million |
Net Cash Flow | $25.49 Million |
Net Cash Flow From Financing Activities, Continuing | $-23.02 Million |
Net Cash Flow, Continuing | $25.49 Million |
Net Cash Flow From Operating Activities | $144.65 Million |
Net Cash Flow From Investing Activities | $-96.15 Million |
Net Cash Flow From Financing Activities | $-23.02 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Benefits Costs and Expenses | $462.21 Million |
Basic Earnings Per Share | $1.36 |
Diluted Earnings Per Share | $1.26 |
Income/Loss From Continuing Operations After Tax | $141.82 Million |
Revenues | $628.55 Million |
Operating Income/Loss | $143.36 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $735000.00 |
Net Income/Loss | $141.82 Million |
Net Income/Loss Attributable To Parent | $141.82 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Preferred Stock Dividends And Other Adjustments | $735000.00 |
Net Income/Loss Available To Common Stockholders, Basic | $140.47 Million |
Income Tax Expense/Benefit | $24.52 Million |
Nonoperating Income/Loss | $22.98 Million |
Income Tax Expense/Benefit, Deferred | $-40.01 Million |
Operating Expenses | $475.39 Million |
Cost Of Revenue | $9.80 Million |
Costs And Expenses | $485.20 Million |
Income/Loss From Continuing Operations Before Tax | $166.34 Million |
Basic Average Shares | $308.91 Million |
Diluted Average Shares | $334.57 Million |
Gross Profit | $618.75 Million |
Research and Development | $231.29 Million |
Selling, General, and Administrative Expenses | $244.10 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Liabilities | $19.21 Million |
Equity Attributable To Parent | $638.84 Million |
Current Assets | $466.98 Million |
Liabilities | $145.42 Million |
Prepaid Expenses | $5.82 Million |
Assets | $784.26 Million |
Liabilities And Equity | $784.26 Million |
Accounts Payable | $18.58 Million |
Equity | $638.84 Million |
Other Current Liabilities | $107.63 Million |
Noncurrent Assets | $317.28 Million |
Current Liabilities | $126.22 Million |
Other Non-current Assets | $314.35 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Fixed Assets | $2.93 Million |
Inventory | $8.05 Million |
Other Current Assets | $453.11 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.